Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885228 | 0.85 | BCHE (0.53) | MEN1KMT2ABCHE | |
| SCHEMBL6886751 | 0.84 | BCHE (0.54) | MEN1KMT2ABCHE | |
| SCHEMBL6155587 | 0.82 | CYSLTR2 (0.44) | MEN1KMT2ABCHEFFAR1APP | |
| SCHEMBL6155248 | 0.82 | CYSLTR2 (0.42) | MEN1KMT2ABCHEFFAR1APP | |
| SCHEMBL2107635 | 0.81 | MGLL (0.46) | CYP4F2CYP4A11MGLLPPARAPPARG | |
| SCHEMBL6155493 | 0.81 | APP (0.44) | APPNR4A1NR4A2NR4A3 | |
| SCHEMBL2107016 | 0.80 | VDR (0.48) | CYP4F2CYP4A11MGLLPPARAPPARG | |
| SCHEMBL6155835 | 0.80 | APP (0.44) | APPNR4A1NR4A2NR4A3 | |
| SCHEMBL6155489 | 0.79 | NR4A2 (0.42) | SMPD1NR4A1NR4A2NR4A3 | |
| SCHEMBL6886826 | 0.79 | RRM1 (0.47) | MEN1KMT2ABCHEAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | claimed |
| US-11730682-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-2836187-B1 | SELF-STANDING COSMETIC SHEET | OREAL (FR) | 2021-12-08 | — | — | EP | disclosed |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | L'OREAL (FR) | 2018-08-23 | — | — | US | disclosed |
| US-9949897-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2018-04-24 | — | — | US | disclosed |
| US-20150209243-A1 | SELF-STANDING COSMETIC SHEET | L'OREAL (FR) | 2015-07-30 | — | — | US | disclosed |
| EP-1658838-B1 | Emulsification system for use in cosmetics | ORÉAL L (FR) | 2014-07-02 | — | — | EP | disclosed |
| US-8158136-B2 | Emulsification system for use in cosmetics | L'ORÉAL (FR) | 2012-04-17 | — | — | US | disclosed |
| US-20070025937-A1 | Cosmetic compositions containing hydroquinone | L'OREAL S.A. (FR) | 2007-02-01 | — | — | US | disclosed |
| US-20050169945-A1 | Composition for protecting keratin material, process of making, uses thereof | L'OREAL (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1559398-A1 | Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins | L'OREAL (FR) | 2005-08-03 | — | — | EP | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | L'OREAL (FR) | 2002-12-26 | — | — | US | disclosed |
| EP-1262168-A1 | Composition containing fibres to combat the skin aging process | L'OREAL (FR) | 2002-12-04 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | CYP24A1, CYP27B1, CYP2R1 | CYP4F2 60/4885CYP4A11 123/4885MGLL 1535/4885 |
| US-20150209243-A1 | SELF-STANDING COSMETIC SHEET | CUTA, SUCLG1, SIGLEC7 | CYP4F2 4804/4885CYP4A11 4810/4885MGLL 499/4885 |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | CUTA, DSG1, SUCLG1 | CYP4F2 4281/4885CYP4A11 4206/4885MGLL 459/4885 |
| US-11730682-B2 | Self-standing cosmetic sheet | CUTA, DSG1, SUCLG1 | CYP4F2 4281/4885CYP4A11 4206/4885MGLL 459/4885 |
| US-20050169945-A1 | Composition for protecting keratin material, process of making, uses thereof | KRT18, PROC, CUTA | CYP4F2 1050/4885CYP4A11 2282/4885MGLL 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.